Komori
Nitto Denko (6988) · InitiativeFirst stated

Joint development of switch-enabled mRNA therapeutics with aceRNA Technologies

First written in FY2022. . Latest entry: FY2022.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Joint development of switch-enabled mRNA therapeutics with aceRNA TechnologiesA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2022First statedAnnual report

    「During the current consolidated fiscal year, we entered into an agreement with aceRNA Technologies Co., Ltd. covering the joint development of switchable mRNA therapeutics and an equity investment.」

    The joint development and equity investment agreement with aceRNA Technologies introduced a drug discovery program combining mRNA technology with our drug delivery technology.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Nitto Denko's next results are scheduled for 2026-10-27. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Joint development of switch-enabled mRNA therapeutics with aceRNA Technologies | NITTO DENKO CORPORATION (6988) | Komori